Public Employees Retirement System of Ohio Sells 433 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Public Employees Retirement System of Ohio cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 58,338 shares of the biopharmaceutical company’s stock after selling 433 shares during the period. Public Employees Retirement System of Ohio’s holdings in Regeneron Pharmaceuticals were worth $61,327,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the last quarter. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $26,000. Sachetta LLC boosted its stake in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $26,000. Finally, Family Firm Inc. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on REGN shares. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, Oppenheimer dropped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,107.29.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $778.00 on Monday. The stock has a market cap of $85.49 billion, a price-to-earnings ratio of 19.25, a PEG ratio of 3.00 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The company has a 50 day simple moving average of $876.85 and a two-hundred day simple moving average of $1,011.88. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.